Trial Condition(s):

Wet Macular Degeneration

Caregiver burden of wet age-related macular degeneration (wAMD) in Japan

Bayer Identifier:

17945

ClinicalTrials.gov Identifier:

NCT02541084

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to proactive therapy especially in real-life rural settings where public transportations are not readily available.

Inclusion Criteria
- [Patients]
 -- Female and male out-patients diagnosed with wAMD.
 -- Patients who are accompanied by his/her caregiver(s).
 -- Patients who have been receiving anti-VEGF therapy with proactive regimen for 12 months or more at the participating site. 
 -- Providing informed consent for the participation in this study.
 - [Caregivers]
 -- Providing informed consent for the participation in this study.
 -- Capable of understanding and completing the questionnaires without any help from others
Exclusion Criteria
- [Patients]
 -- Presence of a disease or a condition more disabling than wAMD in term of caregiving.
 -- Presence of intractable neurologic disease, physical handicap, mental handicap, or any condition that rendered them unable to walk independently.
 -- Intraocular surgery for other eye diseases after the start of wAMD therapy.
 - [Caregivers]
 -- Professional carers

Trial Summary

Enrollment Goal
72
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Japan

Status
Completed
 

Trial Design